Singapore’s MerLion Starts Phase II European Finafloxacin Trials
This article was originally published in PharmAsia News
Executive Summary
MerLion will enroll as many as 258 patients across centers in Germany and Poland for patients requiring hospitalization for urinary tract infections and pyelonephritis, positive signs for a drug in-licensed by Alcon for North America.